aTYR PHARMA INC (ATYR) Financials
Annual revenue, profitability and per-share results for aTYR PHARMA INC, as reported in SEC filings.
Revenue • FY2025
$190K
▼ 19.1%YoY
Net income • FY2025
-$74.12M
▼ 15.8%YoY
Diluted EPS • FY2025
-$0.80
▲ 7.0%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $190K | -$74.12M | — | -$0.80 | -$62.06M | -40856.3% | -19.1% |
| FY2024 | $235K | -$64.02M | — | -$0.86 | -$69.18M | -28899.6% | -33.4% |
| FY2023 | $353K | -$50.39M | — | -$0.94 | -$37.44M | -15557.8% | -96.6% |
| FY2022 | $10.39M | -$45.34M | — | -$1.60 | -$43.53M | -446.8% | — |
Figures as reported in aTYR PHARMA INC's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ATYR filing.
Get an email when ATYR files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.